Blum JL et al. Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor-positive human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial. ESMO 2023;Abstract 461P.
Brufsky A et al. Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis. ASCO 2024;Abstract 1111.
Brufsky A et al. Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: Real-world effectiveness. Oncologist 2024;29(12):1032-43. Abstract
Brufsky A et al. Real-world comparative efficacy of CDK4/6 inhibitors in first-line treatment of HR+/HER2- metastatic breast cancer. San Antonio Breast Cancer Symposium 2024;Abstract P2-09-30.
Brufsky A et al. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: A SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer. Breast Cancer Res Treat 2024;208(2):223-35. Abstract
Brufsky A et al. Real-world effectiveness of palbociclib plus letrozole vs letrozole alone for metastatic breast cancer with lung or liver metastases: Flatiron database analysis. Front Oncol 2022;12. Abstract
Finn RS et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. ASCO 2022;Abstract LBA1003.
Llombart-Cussac A et al. PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study. San Antonio Breast Cancer Symposium 2023;Abstract RF01-03.
Onesti CE, Jerusalem G.CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticancer Ther 2021;21(3):283-98. Abstract
Rocque GB et al. Laboratory monitoring in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer treated with palbociclib in a real-world setting: Results from POLARIS. San Antonio Breast Cancer Symposium 2022;Abstract P3-01-05.
Rocque G et al. Real-world quality of life (QoL) in patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib: Final clinical outcome assessment (COA) analysis from POLARIS. ESMO 2022;Abstract 266P.
Rugo HS et al. Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting. ESMO Open 2025;10(1):104103. Abstract
Rugo HS et al. Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis. ESMO Breast Cancer 2022;Abstract 169P.
Rugo HS et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer 2022;8(1):114. Abstract
Rugo HS et al. Real-world treatment patterns of palbociclib plus an aromatase inhibitor or aromatase inhibitor alone for metastatic breast cancer in the Flatiron database. San Antonio Breast Cancer Symposium 2022;Abstract P3-01-14.
Tripathy D et al. Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS. San Antonio Breast Cancer Symposium 2022;Abstract P3-01-03.
Tripathy D et al. POLARIS: A prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol 2020;16(31):2475-85. Abstract